Expertos Invitados





RESISTENCIA A LA INSULINA, DIABETES MELLITUS E INFLAMACION: SU ASOCIACION CON ENFERMEDAD VASCULAR

(especial para SIIC © Derechos reservados)
La modificación de la dieta y el incremento de la actividad física, al atenuar la disfunción del endotelio y la inflamación, podrían reducir el riesgo de aparición de resistencia a la insulina y diabetes.
barzilay.jpg Autor:
Joshua Barzilay
Columnista Experto de SIIC
Artículos publicados por Joshua Barzilay
Recepción del artículo
5 de Mayo, 2003 		Primera edición
22 de Julio, 2003 		Segunda edición, ampliada y corregida
7 de Junio, 2021

RESISTENCIA A LA INSULINA, DIABETES MELLITUS E INFLAMACION: SU ASOCIACION CON ENFERMEDAD VASCULAR

Resumen
En este artículo resumo un nuevo paradigma para la comprensión de la diabetes mellitus (DM) y resistencia a la insulina (RI) como consecuencia de inflamación. Este paradigma ayuda a explicar por qué la DM y la RI se asocian con elevado riesgo de complicaciones macrovasculares y microvasculares, y también brinda nueva dirección para el tratamiento y la prevención de la DM.


Artículo completo
(castellano)
Extensión:  +/-9.43 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

INSULIN RESISTANCE, DIABETES MELLITUS AND INFLAMMATION: THEIR ASSOCIATION WITH VASCULAR DISEASE

Abstract
In this article I summarize a new paradigm for understanding diabetes mellitus (DM) and insulin resistance (IR) as diseases of inflammation. This paradigm helps to explain why DM and IR are associated with a high risk of macro- and micro-vascular disease. This paradigm also offers direction for the development of new treatments for DM and its prevention.


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Endocrinología y Metabolismo
Relacionadas: Cardiología, Medicina Interna, Nutrición



Comprar este artículo
Extensión: 9.43 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
  2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002 ; 105:1135-43.
  3. Verma S, Anderson T. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546 - 49.
  4. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-35.
  5. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics 2001; 107: E13.
  6. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971 - 77.
  7. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152: 897- 907.
  8. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 639 - 51.
  9. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271 - 78.
  10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity induced insulin resistance. Science 1996; 271: 665 - 68.
  11. Skolnik EY, Marcusohn J. Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Factor Rev 1996; 7: 162 - 73.
  12. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119 - 25.
  13. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32, Suppl 3: 24-34.
  14. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995; 18: 1100-3.
  15. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997 ; 40:1286 - 92.
  16. Festa A, D\'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102:42- 47.
  17. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Satter N. Low grade inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453 - 55.
  18. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation. 1996; 94: 2171-76.
  19. Herlihy OM, Barrow BA, Grant PJ, Levy JC. Hyperglycaemic siblings of type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic siblings. Diabetologia 2002; 45: 635 - 41.
  20. Nakanishi N, Suzuki K, Tatara K. White blood cell count and clustered features of metabolic syndrome in Japanese male office workers. Occup Med (Lond) 2002; 52: 213 - 18.
  21. Nakanishi N, Sato M, Shirai K, et al. Associations between white blood cell count and features of the metabolic syndrome in Japanese male office workers. Ind Health 2002; 40: 273 - 77.
  22. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437 - 41.
  23. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1998; 18: 1199 - 202.
  24. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353: 1649-52.
  25. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327-34.
  26. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes. 2001; 50: 2384 - 89.
  27. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51: 455-61.
  30. Lindsay RS, Krakoff J, Hanson RL, Bennett PH, Knowler WC. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes 2001; 50: 1598 - 1603.
  31. Festa A, D\'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51: 1131 - 37.
  32. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999; 22: 767-72.
  33. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 2002;155: 57-64.
  34. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of c-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016 - 21.
  35. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood-cell count and the risk of impaired fasting glucose or type II diabetes in middle-aged Japanese men. Diabetologia 2002; 45: 42 - 48.
  36. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O\'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002; 51: 1596 - 600.
  37. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228 - 32.
  38. Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabet Med 1996; 13: 59 - 64.
  39. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999; 19: 972 - 78.
  40. Chen N-G, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84: 3485 - 89.
  41. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420 - 26.
  42. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86: 4398 - 4405.
  43. Zwaka TP, Hambach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194 - 97.
  44. Ito A, Tsao PS, Adimoolan S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydolase. Circulation 1999; 99: 3092 - 95.
  45. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89: 1-2.
  46. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531 - 34.
  47. Hennes MM, O\'Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Hypertension. 1996; 28: 120 - 26.
  48. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000; 49: 1939 - 45.
  49. Facchini FS, Humphreys MH, DoNascimento CA, Abbasi F, Reaven GM. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr 2000; 72: 776 - 9.
  50. Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med 2000; 10: 60 - 65.
  51. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002; 136: 201 - 9.
  52. Jarvi A, Karlstrom B, Granfeldt Y, Bjorck I, Asp N-G, Vessby B. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in Type 2 diabetic patients. Diabetes Care 1999; 22:10-18.
  53. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75:492-8.
  54. Ascherio A, Willett W. Health effects of trans fatty acids. Am J Clin Nutr 1997; 66 (suppl): S1006 - 10.
  55. Mensink RPK, Martijn. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990; 323: 439 - 45.
  56. Crawford M. Fatty-acid ratios in free-living and domestic animals: possible implications for atheroma. Lancet 1968: 1329 - 33.
  57. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001; 36: 1007 - 24.
  58. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how Prostaglandins Leukot Essent Fatty Acids 2000; 63: 351 - 62.
  59. Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41:826-34.
  60. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47:699-713.
  61. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13 - 20.
  62. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002; 109: 1321 - 6.
  63. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306 - 12.
  64. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451 - 58.
  65. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357 - 62.
  66. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161:2185-92.
  67. Johansen O, Seljeflot I, Hostmark AT, Arnesen H. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1681-6.
  68. Seljeflot I, Arnesen H, Brude IR, Nenseter MS, Drevon CA, Hjermann I. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest 1998; 28:629-35.
  69. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71:213S-23S.
  70. Goode GK, Garcia S, Heagerty AM. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 1997; 96:2802-7.
  71. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998; 18:723-31.
  72. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised clinical trial. Lancet 2003; 361: 477 - 85.
  73. He K, Merchant A, Rosner BA, Stampfer MJ, Willett WC, Ascherio A. Fish consumption and risk of stroke in men. JAMA 2002; 288: 3130 - 36.
  74. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747 - 57.
  75. Hu FB, Willett WC. Optimal diets for prevention of heart disease. JAMA 2002; 288: 2569 - 78.
  76. Maiorana A, O\'Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001; 38:860-6.
  77. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-9.
  78. Perseghin G, Price TB, Petersen KF, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996; 335:1357-62.
  79. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol [see comments]. N Engl J Med 1998; 339:12-20.
  80. Buemann B, Tremblay A. Effects of exercise training on abdominal obesity and related metabolic complications. Sports Med 1996; 21:191-212.
  81. Watts NB. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results. J Reprod Med 2002; 47:82-92.
  82. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:653-63.
  83. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281:1722-7.
Título español
Resumen
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
  Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008